Dr. Reddy's biosimilar for Bristol's Orencia undergoes FDA review
Source: SeekingAlpha
2026-02-20 11:40:07 ET
More on Bristol-Myers Squibb Company, Dr. Reddy's
- Bristol-Myers: I'm Buying Post Earnings
- Bristol-Myers Squibb: Oncology Franchise Remains A Core Strength
- Bristol-Myers: Walking Blindfolded To A $30 Billion Patent Cliff
- NIH director reportedly being tapped as acting CDC director
- AstraZeneca, Bristol partner with Evinova to use AI in drug development
Read the full article on Seeking Alpha
For further details see:
Dr. Reddy’s biosimilar for Bristol’s Orencia undergoes FDA review
Dr. Reddy's Laboratories Ltd
NASDAQ: RDY
RDY Trading
0.95% G/L:
$14.3495 Last:
611,970 Volume:
$14.37 Open:
RDY Latest News
February 20, 2026 10:57:00 am
Dr. Reddy's Announces USFDA Acceptance to Review Its Biologics License Application (BLA) for Proposed Interchangeable Biosimilar, Abatacept
RDY Stock Data
$11,719,925,601
612,073,010
N/A
98
N/A
Pharmaceuticals
Healthcare
IN
Hyderabad
